 |
Products |
|
Customer Service |
All products shown on this website might not be available on all markets.
|
In Product Area Transplantation we develop optimised solutions for organ, tissue and cell preservation in connection with transplantation.
|
 |
| |
| XVIVO to be a more independent unit
(2012-05-02)
|
|
|
|
| Vitrolife’s subsidiary Xvivo, with business activities within the organ transplant area, is in an intensive and exciting development phase which now requires greater focus, and will thus become a more independent unit within the Vitrolife Group. Vitrolife’s former CEO Magnus Nilsson will, as the CEO of Xvivo, be able to focus entirely on this line of business. The Board intends to propose to the shareholders that Magnus be given the opportunity to buy into the company and become the owner of approximately 15% of Xvivo. Xvivo will also have an external Board. |
 Read more |
|
|
| Vitrolife´s CEO to focus on Transplantation
(2012-05-02)
|
|
|
|
| ”During Magnus Nilsson’s nine year as CEO, Vitrolife has reached the three, early set, strategic objectives for the company’s fertility business; world leading production infrastructure, complete IVF product portfolio and global sales organisation, which has made the company world leading within the business of fertility treatment products,” says Vitrolife’s chairman Patrik Tigerschiöld. |
| Read more |
|
|
| First third of STEEN study in USA complete
(2012-05-02)
|
|
|
|
| The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a transplant. The first transplantation was carried out in September and four transplantations have thus now been carried out at four centres. A fifth centre, Duke University, has been included in the study, and it is anticipated that they will be able to start within approximately one month there. |
| Read more |
|
|
|
|
|
